Celldex Therapeutics, Inc.
CLDX
$41.95
-$0.66-1.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -50.57% | -58.59% | -63.91% | -45.73% | -32.88% |
| Total Depreciation and Amortization | 1.52% | 3.00% | 6.39% | 8.53% | 7.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.81% | 44.09% | 64.10% | 68.03% | 51.64% |
| Change in Net Operating Assets | 292.42% | 252.89% | 165.08% | 153.76% | -295.06% |
| Cash from Operations | -26.52% | -29.53% | -33.70% | -13.71% | -53.25% |
| Capital Expenditure | -185.05% | -122.17% | -41.43% | -19.68% | -59.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -136.30% | 246.82% | 173.48% | 137.20% | 132.10% |
| Cash from Investing | -140.78% | 250.19% | 172.06% | 136.61% | 131.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 17,207.25% | -54.63% | -99.46% | -99.78% | -99.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 17,207.25% | -54.63% | -99.46% | -99.78% | -99.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 223.94% | 118.98% | 107.97% | -102.37% | -235.69% |